IRLAB Therapeutics AB (publ) (IRLAB-A) — Working Capital to Net Assets Ratio
IRLAB Therapeutics AB (publ) (IRLAB-A) has a Working Capital to Net Assets ratio of -70.4% as of December 2025. Working capital of Skr-21.62 Million (current assets of Skr85.87 Million minus current liabilities of Skr107.49 Million) is measured against net assets of Skr30.72 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See IRLAB Therapeutics AB (publ) (IRLAB-A) balance sheet quality index to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
IRLAB Therapeutics AB (publ) Working Capital to Net Assets (2014–2025)
This chart shows how IRLAB Therapeutics AB (publ)'s Working Capital to Net Assets ratio has evolved across 12 annual periods from 2014 to 2025. As of December 2025, the ratio stands at -70.4%, reflecting working capital of Skr-21.62 Million against net assets of Skr30.72 Million SEK. Check how tangible is IRLAB Therapeutics AB (publ)'s equity to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for IRLAB Therapeutics AB (publ) (2014–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for IRLAB Therapeutics AB (publ) from 2014 to 2025, covering 12 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see IRLAB-A company net worth.
| Year | WC/NA Ratio | Working Capital (SEK) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | -70.4% | Skr-21.62 Million | Skr30.72 Million | Skr85.87 Million | Skr107.49 Million | ▼ -7.6 pp |
| 2024 | -62.8% | Skr-20.48 Million | Skr32.63 Million | Skr79.56 Million | Skr100.04 Million | ▼ -137.8 pp |
| 2023 | 75.0% | Skr86.86 Million | Skr115.76 Million | Skr123.59 Million | Skr36.73 Million | ▼ -6.2 pp |
| 2022 | 81.3% | Skr236.34 Million | Skr290.83 Million | Skr268.68 Million | Skr32.34 Million | ▼ -6.9 pp |
| 2021 | 88.1% | Skr352.04 Million | Skr399.48 Million | Skr421.44 Million | Skr69.40 Million | ▲ +12.6 pp |
| 2020 | 75.5% | Skr262.82 Million | Skr347.88 Million | Skr283.74 Million | Skr20.92 Million | ▲ +22.5 pp |
| 2019 | 53.1% | Skr96.54 Million | Skr181.83 Million | Skr119.88 Million | Skr23.34 Million | ▼ -7.2 pp |
| 2018 | 60.2% | Skr128.01 Million | Skr212.48 Million | Skr140.47 Million | Skr12.46 Million | ▲ +14.9 pp |
| 2017 | 45.3% | Skr70.25 Million | Skr155.00 Million | Skr78.22 Million | Skr7.97 Million | ▲ +26.7 pp |
| 2016 | 18.6% | Skr19.37 Million | Skr103.89 Million | Skr28.19 Million | Skr8.82 Million | ▲ +6.9 pp |
| 2015 | 11.7% | Skr10.79 Million | Skr92.03 Million | Skr16.07 Million | Skr5.28 Million | ▼ -6.1 pp |
| 2014 | 17.8% | Skr15.77 Million | Skr88.57 Million | Skr21.11 Million | Skr5.34 Million | — |